01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Apitope, Merck KGaA deal

Merck returned global rights to multiple sclerosis candidate ATX-MS-1467 to Apitope, terminating the partners’ 2009 deal. The vaccine containing four synthetic peptides derived from human myelin basic protein has completed a Phase IIa trial to...
07:00 , Oct 17, 2016 |  BC Extra  |  Company News

Merck KGaA returns rights to Apitope's vaccine

Apitope International N.V. (Diepenbeek, Belgium) said Merck KGaA (Xetra:MRK) returned global rights to multiple sclerosis candidate ATX-MS-1467 . Apitope did not disclose a reason for why Merck KGaA handed back the molecule. This quarter, Apitope...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Completed Phase IIa enrollment

Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467 doses are titrated during the first 4 weeks of treatment. Merck has exclusive, worldwide rights to develop and...
07:00 , Oct 16, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Big drive for big data In the last month, the NIH has pledged almost $100 million for big data programs aimed at making information usable and accessible to the wider research community and to create...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Phase I data

An open-label, international Phase I trial in 43 patients with relapsing MS showed that 5 dose levels of intradermal ATX-MS-1467 every 2 weeks for 16 weeks led to a significant reduction in the number of...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Completed Phase I enrollment

Apitope completed enrollment of an open-label, international Phase I trial evaluating 5 dose levels of intradermal and subcutaneous ATX-MS-1467 every 2 weeks for 16 weeks in about 40 patients. The administration of the first dose...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Phase I started

Apitope began a U.K. Phase I trial in 40 patients to evaluate intra-dermal or subcutaneous ATX-MS-1467 given every 2 weeks for 16 weeks, followed by a 24-week follow-up period. Apitope is developing ATX-MS-1467 with Merck's...
07:00 , May 28, 2009 |  BC Innovations  |  Strategy

Fast Forward in MS

Fast Forward LLC , a not-for-profit venture firm spun out of the National Multiple Sclerosis Society in the U.S., has partnered with EMD Serono Inc. to fill the funding gap between preclinical research and drug...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

Apitope, Merck KGaA deal

Merck KGaA's Merck Serono S.A. subsidiary received exclusive, worldwide rights to develop and commercialize Apitope's ATX-MS-1467 . The vaccine containing four peptides derived from human myelin basic protein has completed a Phase I/IIa trial to...